Cited by 298Atrial Fibrillation Management and OutcomesInflammatory Biomarkers in Disease PrognosisAcute Ischemic Stroke Management

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., Wallentin, L.·2013·European Heart Journal

Abstract

Assessment of atrial fibrillation (AF)-associated stroke risk is at present mainly based on clinical risk scores such as CHADS2 and CHA2DS2-VASc, although these scores provide only modest discrimination of risk for individual patients. Biomarkers derived from the blood may help refine risk assessment in AF for stroke outcomes and for mortality. Recent studies of biomarkers in AF have shown that they can substantially improve risk stratification. Cardiac biomarkers, such as troponin and natriuretic peptides, significantly improve risk stratification in addition to current clinical risk stratification models. Similar findings have recently been described for markers of renal function, coagulation, and inflammation in AF populations based on large randomized prospective clinical trials or large community-based cohorts. These new findings may enable development of novel tools to improve clinical risk assessment in AF. Biomarkers in AF may also improve the understanding of the pathophysiology of AF further as well as potentially elucidate novel treatment targets. This review will highlight novel associations of biomarkers and outcomes in AF as well as recent progress in the use of biomarkers for risk stratification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht024

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even short episodes of AF lead to myocardial damage and expression of prothrombotic factors on the atrial endothelial surface, and activation of platelets and inflammatory cells, and contribute to a generalized prothrombotic state.

    “Furthermore, even short episodes of AF lead to myocardial damage and expression of prothrombotic factors on the atrial endothelial surface, and activation of platelets and inflammatory cells, and contribute to a generalized prothrombotic state.88,89”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N -9N.
  2. Wallentin L, Hijazi Z, Siegbahn A, Schollin M, Alexander JH, Atar D, Bernard, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJV, Granger CB. on behalf of the ARISTOTLE Investigators. High sen- sitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. European Heart Journal 2012;33 (Abstract Supplement 53).
  3. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EH, Lopes ED, McMurray JJV, Granger CB. NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. European Heart Journal 2012;33. (Abstract Supplement, 51).
  4. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342 -2348.
  5. Christersson C, Schollin M, Alexander JH, Bersh BJ, Horowitz J, Hylek EM, Mohan P, Granger CB, Wallentin L, Siegbahn A. Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death. European Heart Journal 2012;33 (Abstract Supplement, 51, Abstract session 5297). 105. Siegbahn A, Christersson C, Schollin M, Alexander JH, Horowitz J, Hylek EM, Lopes RD, Mohan P, Granger CB, Wallentin L. Increased levels of D-dimer iden- tify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE sub- study. European Heart Journal 2012;33: (Abstract Supplement 51). 106.

Cited by

Sorted by citations

Authors
Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., & Wallentin, L.
Affiliations
  • Uppsala University (SE)
  • Duke Medical Center (US)
Corresponding author
Hijazi, Z.
Venue
European Heart Journal
Published
2013-02-05
Volume
34
Issue
20
Pages
1475-1480
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2169206499
Cited by
298
References
143
Citations by year
2026: 6 · 2025: 18 · 2024: 15 · 2023: 15 · 2022: 18 · 2021: 27 · 2020: 26 · 2019: 25 · 2018: 22 · 2017: 38 · 2016: 31 · 2015: 20 · 2014: 22 · 2013: 15
FWCI
4.93
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
Keywords
atrial fibrillation, biomarkers, stroke risk, risk stratification, CHA2DS2-VASc score, CHADS2 score, troponin, natriuretic peptides, renal function markers, coagulation markers, inflammatory markers, mortality, pathophysiology
MeSH terms
Atrial Fibrillation, C-Reactive Protein, Echocardiography, Fibrin Fibrinogen Degradation Products, Forecasting, Glomerular Filtration Rate, Humans, Biomarkers, Interleukin-6, Risk Assessment, Troponin I, Natriuretic Peptide, Brain, Cystatin C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review